Sri Lanka Pharmaceuticals & Healthcare Report Q2 2018
Sri Lanka’s pharmaceutical and healthcare expenditure will continue to expand over the forecast period, driven byhealthcare system development and rising demand for chronic disease treatment. Despite rising consumption of brandedmedicines, growing volume sales of lower-cost drugs will continue to underpin market growth in the near term, given low per capitapharmaceutical expenditure. Meanwhile, the government incentive to localise pharmaceutical production will continue to graduallyreshape the competitive landscape in the country. Although we expect foreign investment to increase given the market's long-termdevelopment potential, the country's limited commercial rewards means multinational drugmakers will have little incentive to investand develop a large manufacturing presence in the country in the near term.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook